A startup that’s planning to launch a $60 million drug-manufacturing plant sees big growth in contract manufacturing.
2020 Innovation Issue: Brothers share a knack for creating life sciences companies
Philip and Martin Low’s latest venture, Eradivir, was incorporated in February to develop a treatment that would fight the influenza virus, but COVID-19 prompted a tweak to the business plan.Read More
IU team pursuing breathtaking advancements in regenerative medicine
The emerging health care field seeks to develop methods for replacing or reinvigorating damaged human organs, cells and tissues.Read More
Lilly teams with Canadian biotech in race to find treatment for COVID-19
The Indianapolis-based drugmaker said it will combine its capability for quickly developing antibodies with AbCellera’s “rapid pandemic response platform,” with the goal of getting a treatment into clinics for human testing within four months.Read More
Butler researchers point to way to stop deadly coronavirus from spreading
Dr. Christopher Stobart and his students are focusing on an enzyme in the virus that could inhibit its replication, and plan to submit the findings to a virology journal in coming months.Read More
The medical school said it is testing the use of tezampanel, an experimental drug for migraines developed by Indianapolis-based drugmaker Eli Lilly and Co., to treat opioid withdrawal syndrome and other addictions and mental illnesses.
Some of the vaccine trials in the United States are taking place at Indiana University School of Medicine in Indianapolis.
The grant will help fund an ongoing study to evaluate long-term health outcomes for cancer patients who receive life-saving chemotherapy treatments that often have difficult side effects.
Under the agreement, researchers will study patients who used Lilly autoimmune therapies that are under consideration for the treatment of other autoimmune diseases, including inflammatory bowel disease and psoriasis.
West Lafayette-based Bioanalytical Systems’ latest executive departure comes amid recent signs of stability, turnaround and growth for a company that just three years ago was on the verge of sinking.
The International Council of Motorsport Sciences, established in Indianapolis in 1988, will relocate from Texas later this month after hiring veteran motorsports exec Tom Weisenbach as its new executive director.
Development Corp., is helping raise money for a women-focused cancer research initiative. The campaign, which will run through June, is in its second year.
For companies that pursue technological advances and innovative solutions, bias can have an enduring impact, making it easy for the cycle to be perpetuated.
Around the world, more than 80 vaccine projects are under development by pharmaceutical companies and university research laboratories.
The not-for-profit and its health research are a testament to the idea that all innovation is related—even when the connection appears tenuous at first glance.
Patient data is increasingly in the hands of for-profit industries. Insurance firms and other for-profit companies have been collecting patient data that yields important information that could be used to shape medical care and health policy.
Mucus may be gross, but we produce a lot of it. And new research is uncovering just how beneficial it is in the human body.
The spinoff, called Sexton Biotechnologies, has raised $5 million in outside investment and will spin off in October. The biotech develops cell and gene therapy tools used to grow cells for medical purposes.
After building and selling three companies and starting a fourth, Dr. Don Brown thought he had seen it all. Even so, he still gets an occasional surprise.
Should you avoid red meat? No. Should you strive for 10,000 steps a day? Not unless you just want to. So says Dr. Aaron Carroll, a pediatrician and researcher at the Indiana University School of Medicine who sees it as his life’s calling to debunk what he considers health myths and weak medical research.
Carroll uses Twitter, a New York Times column, blog post, podcast, videos and books to publish his findings on just about any health issue he thinks needs explaining or correcting.
In recent months, the drugmaker has won federal approval to sell a drug called Emgality for two conditions: migraine pain and cluster headaches.